GO:0030429 kynureninase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030429 kynureninase activity is a molecular function defined as the catalysis of L-kynurenine + H2O = anthranilate + L-alanine + H+, and it also acts on 3'-hydroxykynurenine and some other (3-arylcarbonyl)-alanines.
• Kynureninase is a pyridoxal-5'-phosphate (PLP)-dependent enzyme that sits at a critical branch point of the kynurenine pathway of tryptophan metabolism.
• The enzyme determines whether kynurenine is converted toward anthranilate and NAD+ synthesis or toward neuroactive metabolites such as kynurenic acid and quinolinic acid.
• Loss of kynureninase function is linked to NAD deficiency and congenital malformations in humans, and niacin supplementation can rescue the phenotype in model systems.
• Kynureninase activity is elevated in some cancers, including breast cancer metastasis, and kynureninase-expressing antigen-presenting cells can subvert kynurenine-induced AHR activation in CD8 T cells.
• CRISPR knockout, point-mutation, knock-in and overexpression models are powerful tools to dissect the causal role of kynureninase activity in metabolism, immunity and disease.
Description
Kynureninase activity (GO:0030429) is a molecular function that catalyzes the hydrolysis of L-kynurenine to anthranilate and L-alanine, and it also acts on 3'-hydroxykynurenine and some other (3-arylcarbonyl)-alanines. This reaction is a central step in the kynurenine pathway of tryptophan metabolism, a route that produces NAD+ precursors as well as neuroactive and immunomodulatory metabolites. Because the kynurenine pathway branches at multiple points, the catalytic activity of kynureninase helps determine the metabolic fate of kynurenine and the balance between downstream products. Researchers study GO:0030429 to understand how cells maintain NAD+ homeostasis, how immune cells are regulated by tryptophan metabolites, and how dysregulated kynurenine metabolism contributes to cancer and developmental disorders. The enzyme is a pyridoxal-5'-phosphate (PLP)-dependent protein, and its mechanism has been characterized in structural and kinetic studies. In this article, we summarize the definition, mechanism, key genes, disease links, and experimental models relevant to kynureninase activity, with a focus on how CRISPR-based approaches can be used to interrogate its function.
kynureninase activity At A Glance
| GO ID | GO:0030429 |
|---|---|
| GO term | kynureninase activity |
| Ontology | molecular_function |
| Synonym | kynurenine hydrolase activity; L-kynurenine hydrolase activity |
| Definition | Catalysis of the reaction: L-kynurenine + H2O = anthranilate + L-alanine + H+. Also acts on 3'-hydroxykynurenine and some other (3-arylcarbonyl)-alanines. |
| Major function | Hydrolysis of L-kynurenine and related substrates in the kynurenine pathway of tryptophan metabolism |
| Cofactor | Pyridoxal-5'-phosphate (PLP) |
| Pathway context | Kynurenine pathway; links tryptophan catabolism to NAD+ synthesis and neuroactive metabolite production |
| Substrates | L-kynurenine, 3'-hydroxykynurenine, some (3-arylcarbonyl)-alanines |
| Products | Anthranilate, L-alanine, H+ (and corresponding products from alternative substrates) |
What Is GO:0030429?
According to the QuickGO definition, kynureninase activity (GO:0030429) is the catalysis of the reaction L-kynurenine + H2O = anthranilate + L-alanine + H+. The enzyme also acts on 3'-hydroxykynurenine and some other (3-arylcarbonyl)-alanines. In simpler terms, kynureninase is a hydrolase that cleaves L-kynurenine into anthranilate and L-alanine, and it can also process related substrates such as 3'-hydroxykynurenine. This activity is part of the kynurenine pathway, which converts tryptophan into several biologically active metabolites and NAD+ precursors. The reaction requires pyridoxal-5'-phosphate (PLP) as a cofactor, and the enzyme belongs to the PLP-dependent hydrolase family. The official synonyms for this activity are kynurenine hydrolase activity and L-kynurenine hydrolase activity.
Why Is kynureninase activity Important in Cell Biology?
Kynureninase activity is important because it controls a key branch point in the kynurenine pathway, influencing the production of NAD+ precursors and neuroactive metabolites. Dysregulation of this activity has been implicated in developmental disorders, cancer progression, and immune regulation. Understanding GO:0030429 therefore provides insight into fundamental metabolic control and offers potential therapeutic targets for diseases linked to tryptophan metabolism.
• Kynureninase activity determines the metabolic fate of L-kynurenine, directing it toward anthranilate and NAD+ synthesis rather than toward kynurenic acid or quinolinic acid.
• Loss of kynureninase function can cause NAD deficiency and congenital malformations, which can be rescued by niacin supplementation in model systems.
• Elevated kynureninase activity is associated with breast cancer metastasis progression, suggesting a role in tumor metabolic reprogramming.
• Kynureninase-expressing antigen-presenting cells can subvert kynurenine-induced AHR activation in CD8 T cells, linking this activity to immune tolerance.
• Quinolinate, a downstream metabolite of the kynurenine pathway, promotes macrophage-induced immune tolerance in glioblastoma through NMDAR/PPARγ signaling, highlighting the pathway's role in cancer immunity.
• Kynureninase is a PLP-dependent enzyme, making it a model system for studying cofactor-dependent hydrolase mechanisms.
• Regulation of kynureninase activity affects systemic tryptophan availability and can influence neurological and immunological processes.
• Biomimetic co-delivery of simvastatin and kynureninase has been explored for tumor metabolic reprogramming and immunotherapy, showing translational potential.
• Kynureninase activity is a potential biomarker for cancers with altered kynurenine metabolism.
• CRISPR-based editing of kynureninase genes enables causal testing of its role in metabolism, immunity, and development.
Molecular Mechanism of kynureninase activity
Substrate binding and cofactor requirement
In simple terms: Kynureninase needs a helper molecule called PLP to grab its substrate and start the reaction.
Kynureninase is a pyridoxal-5'-phosphate (PLP)-dependent enzyme. The PLP cofactor is covalently linked to a lysine residue in the active site and forms a Schiff base with the substrate L-kynurenine, activating it for hydrolysis. This cofactor requirement is a hallmark of the enzyme family and is essential for catalytic activity.
Catalytic hydrolysis of L-kynurenine
In simple terms: The enzyme cuts L-kynurenine into two pieces: anthranilate and L-alanine.
The catalytic mechanism involves the hydrolysis of L-kynurenine to anthranilate and L-alanine, with the release of a proton. The reaction proceeds through a series of PLP-stabilized intermediates, including a quinonoid intermediate, and results in cleavage of the Cβ–Cγ bond of the substrate. The enzyme also acts on 3'-hydroxykynurenine and some other (3-arylcarbonyl)-alanines, indicating a broad substrate tolerance for related compounds.
Branch point in the kynurenine pathway
In simple terms: Kynureninase is like a traffic controller that sends kynurenine down one of several metabolic roads.
Kynureninase activity competes with other enzymes that metabolize L-kynurenine, such as kynurenine aminotransferases and kynurenine 3-monooxygenase. By converting L-kynurenine to anthranilate, kynureninase directs the pathway toward NAD+ synthesis and away from the production of neuroactive metabolites like kynurenic acid and quinolinic acid. This branch point is critical for maintaining metabolic balance and is regulated by substrate availability and enzyme expression.
Role in NAD+ synthesis and downstream metabolism
In simple terms: The products of kynureninase feed into the production of NAD+, a vital molecule for energy metabolism.
Anthranilate produced by kynureninase is further metabolized to quinolinate, which is a precursor for NAD+ synthesis. This link to NAD+ production explains why loss of kynureninase function can lead to NAD deficiency and associated developmental defects. The enzyme therefore connects tryptophan catabolism to cellular energy metabolism and redox balance.
Regulation by substrate and inhibitors
In simple terms: The speed of the kynureninase reaction can be turned up or down by the availability of its substrate and by other molecules.
Kynureninase activity is influenced by the concentration of L-kynurenine and by the presence of inhibitors or alternative substrates. Some (3-arylcarbonyl)-alanines can act as substrates or inhibitors, modulating the enzyme's effective activity. Additionally, the expression level of the kynureninase gene and the availability of PLP cofactor can regulate flux through this step.
Key Genes Involved in GO:0030429 kynureninase activity
The following genes and proteins are directly or indirectly involved in kynureninase activity and the kynurenine pathway.
| Gene | Major Role | Research Relevance |
|---|---|---|
| KYNU | Encodes kynureninase, the enzyme responsible for GO:0030429 activity | Mutations cause NAD deficiency and congenital malformations; target for cancer and immune studies |
| KMO | Kynurenine 3-monooxygenase, converts kynurenine to 3-hydroxykynurenine | Competes with kynureninase for substrate; elevated in breast cancer metastasis |
| KYAT1 | Kynurenine aminotransferase, produces kynurenic acid | Alternative branch of kynurenine pathway; affects neuroactive metabolite balance |
| KYAT2 | Kynurenine aminotransferase, produces kynurenic acid | Alternative branch of kynurenine pathway |
| KYAT3 | Kynurenine aminotransferase, produces kynurenic acid | Alternative branch of kynurenine pathway |
| TDO2 | Tryptophan 2,3-dioxygenase, initiates kynurenine pathway | Upstream of kynureninase; regulates substrate supply |
| IDO1 | Indoleamine 2,3-dioxygenase 1, initiates kynurenine pathway | Upstream of kynureninase; immune regulation |
| IDO2 | Indoleamine 2,3-dioxygenase 2, initiates kynurenine pathway | Upstream of kynureninase |
| QPRT | Quinolinate phosphoribosyltransferase, converts quinolinate to NAD+ | Downstream of kynureninase; links to NAD+ synthesis |
| HAAO | 3-hydroxyanthranilate 3,4-dioxygenase, produces quinolinate | Downstream of kynureninase; NAD+ synthesis |
| ACMSD | Aminocarboxymuconate semialdehyde decarboxylase, regulates quinolinate levels | Downstream of kynureninase; affects NAD+ production |
| AHR | Aryl hydrocarbon receptor, binds kynurenine | Mediates immune effects of kynurenine; kynureninase-expressing APCs subvert AHR activation |
| NMDAR | N-methyl-D-aspartate receptor, responds to quinolinate | Mediates quinolinate-induced immune tolerance in glioblastoma |
| PPARG | Peroxisome proliferator-activated receptor gamma | Involved in quinolinate signaling in glioblastoma |
| PLP | Pyridoxal-5'-phosphate, cofactor for kynureninase | Essential for catalytic activity; not a gene but a metabolite |
| NADSYN1 | NAD synthetase 1, final step of NAD+ synthesis | Downstream of kynureninase; NAD+ homeostasis |
| SLC7A5 | L-type amino acid transporter, transports tryptophan and kynurenine | Affects substrate availability for kynureninase |
How Is kynureninase activity Regulated?
Kynureninase activity is regulated at multiple levels. Transcriptionally, the KYNU gene can be induced by inflammatory cytokines and other signals that activate the kynurenine pathway. Post-translationally, the enzyme requires PLP cofactor availability, and its activity can be modulated by substrate concentration and by inhibitors such as (3-arylcarbonyl)-alanines. In the context of cancer, kynureninase activity is elevated in metastatic breast cancer, suggesting regulation by tumor microenvironment factors. Additionally, kynureninase-expressing antigen-presenting cells can regulate T cell responses by modulating kynurenine availability for AHR activation. These regulatory mechanisms ensure that kynureninase activity is tuned to cellular metabolic needs and immune context.
kynureninase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KYNU | NAD deficiency, congenital malformations | KYNU knockout mice; patient-derived iPSCs; niacin rescue |
| KYNU | Breast cancer metastasis | KYNU overexpression in breast cancer cell lines; xenograft models |
| KYNU | Immune tolerance in cancer | KYNU-expressing antigen-presenting cells; CD8 T cell co-culture |
| KMO | Breast cancer metastasis | KMO knockout or overexpression in cancer cells |
| AHR | Kynurenine-mediated immune suppression | AHR reporter assays; AHR knockout T cells |
Kynureninase deficiency and congenital malformations
Loss-of-function mutations in KYNU, which encodes kynureninase, cause NAD deficiency and congenital malformations in humans. This condition is characterized by vertebral, cardiac, renal, and limb defects, and can be rescued by niacin (vitamin B3) supplementation in model systems. The mechanism involves impaired conversion of L-kynurenine to anthranilate, reducing downstream NAD+ synthesis. This highlights the critical role of GO:0030429 in development and the potential for nutritional intervention.
Kynureninase in cancer progression and metastasis
Elevated kynureninase activity is associated with breast cancer metastasis progression, alongside increased kynurenine monooxygenase activity. This suggests that tumor cells may upregulate kynureninase to support metabolic reprogramming and immune evasion. In glioblastoma, quinolinate produced downstream of kynureninase promotes macrophage-induced immune tolerance through NMDAR/PPARγ signaling. Targeting kynureninase activity could therefore be a therapeutic strategy in cancers with dysregulated tryptophan metabolism.
Kynureninase and immune regulation
Kynureninase-expressing antigen-presenting cells can subvert kynurenine-induced AHR activation in CD8 T cells, thereby modulating immune responses. This indicates that kynureninase activity in the tumor microenvironment can suppress anti-tumor immunity. Biomimetic co-delivery of simvastatin and kynureninase has been explored to reprogram tumor metabolism and enhance immunotherapy. These findings link GO:0030429 to immune tolerance and suggest that inhibiting kynureninase could boost cancer immunotherapy.
Kynureninase in neurological and metabolic disorders
The kynurenine pathway is implicated in neurological disorders because its metabolites can be neuroactive or neurotoxic. Kynureninase activity influences the balance between neuroprotective kynurenic acid and neurotoxic quinolinic acid. Dysregulation of this balance has been associated with neurodegenerative and psychiatric conditions, although direct evidence for kynureninase mutations in these diseases is still emerging. Further research using CRISPR models is needed to establish causality.
From kynureninase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of kynureninase activity cause NAD deficiency? | KYNU knockout cell lines and mouse models |
| Does kynureninase overexpression promote cancer metastasis? | KYNU overexpression in breast cancer cell lines and xenografts |
| How does kynureninase in APCs affect CD8 T cell function? | KYNU-expressing antigen-presenting cells co-cultured with CD8 T cells |
| Can kynureninase inhibition enhance immunotherapy? | Biomimetic co-delivery of simvastatin and kynureninase in tumor models |
| What is the catalytic mechanism of kynureninase? | Recombinant kynureninase with point mutations in active site; kinetic assays |
| How does kynureninase activity affect quinolinate production? | KYNU knockout cells treated with kynurenine; quinolinate measurement |
How to Study the kynureninase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic activity assay | Conversion of L-kynurenine to anthranilate | Kinetic characterization of wild-type and mutant kynureninase |
| LC-MS metabolomics | Levels of kynurenine pathway metabolites | Assessing pathway flux in cells and tissues |
| CRISPR knockout screen | Genes affecting kynureninase activity or NAD+ levels | Identifying modifiers of the kynurenine pathway |
| RNA-seq | Transcriptional changes upon kynureninase perturbation | Mapping downstream gene expression networks |
| Proteomics | Protein expression and interactions | Identifying kynureninase binding partners |
| Co-culture assays | T cell activation and cytokine production | Studying immune modulation by kynureninase-expressing APCs |
| Xenograft models | Tumor growth and metastasis | Testing kynureninase overexpression or inhibition in vivo |
| Biomimetic delivery | Tumor metabolic reprogramming | Evaluating combination immunotherapy |
Enzymatic activity assays
Kynureninase activity can be measured using spectrophotometric or HPLC-based assays that monitor the conversion of L-kynurenine to anthranilate and L-alanine. These assays are typically performed with recombinant enzyme or cell lysates and can be used to determine kinetic parameters and inhibitor effects. They are essential for validating the functional impact of CRISPR edits.
Metabolomics and flux analysis
Metabolomic profiling by mass spectrometry can quantify kynurenine pathway metabolites, including L-kynurenine, anthranilate, kynurenic acid, and quinolinic acid, providing a readout of kynureninase activity in cells and tissues. Stable isotope tracing can further assess flux through the pathway. These methods are powerful for studying how genetic perturbations alter metabolic networks.
CRISPR screening and functional genomics
CRISPR knockout screens can identify genes that modulate kynureninase activity or its downstream effects, such as NAD+ synthesis and immune regulation. Pooled screens with metabolite-based selection or reporters can uncover synthetic lethal interactions. These approaches are complemented by transcriptomic and proteomic analyses.
Immunological and co-culture assays
To study the role of kynureninase in immune regulation, co-culture systems with antigen-presenting cells and CD8 T cells can be used, measuring T cell proliferation, cytokine production, and AHR activation. These assays help dissect how kynureninase-expressing cells modulate immune responses. They are also useful for testing immunotherapies targeting the kynurenine pathway.
How CRISPR Can Be Used to Study GO:0030429 kynureninase activity
Knockout
CRISPR knockout of KYNU can abolish kynureninase activity, leading to accumulation of L-kynurenine and reduced anthranilate and NAD+ levels. This model is useful for studying the consequences of loss of function in development, cancer, and immunity. Knockout cell lines can be validated by enzymatic assays and metabolomics.
Point Mutation
Point mutations in the KYNU active site can be introduced to dissect catalytic residues and cofactor binding. Such models help distinguish between loss of catalytic activity and loss of protein expression. They are valuable for understanding the mechanism of kynureninase and for validating inhibitor specificity.
Knock-in
Knock-in of tagged KYNU (e.g., FLAG or GFP) allows for affinity purification and imaging of the enzyme in live cells. This approach can reveal subcellular localization and interaction partners. Knock-in of disease-associated mutations can model human disorders.
Overexpression
Overexpression of KYNU can elevate kynureninase activity, mimicking the elevated activity seen in metastatic breast cancer. This model is useful for studying the effects of increased flux through the kynurenine pathway on tumor growth and immune evasion. It can also be used to test inhibitors.
How EDITGENE Supports kynureninase activity Research
Researchers studying kynureninase activity-related genes often need to determine whether a candidate gene is causally involved in metabolic, developmental, or immune phenotypes. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell models, enabling rigorous functional studies of GO:0030429 and its associated pathways.
Contact EDITGENE today to design your custom CRISPR model for kynureninase activity research.
Frequently Asked Questions About kynureninase activity
What is kynureninase activity?
Kynureninase activity (GO:0030429) is the catalysis of the reaction L-kynurenine + H2O = anthranilate + L-alanine + H+. It also acts on 3'-hydroxykynurenine and some other (3-arylcarbonyl)-alanines.
What genes are involved in kynureninase activity?
The primary gene is KYNU, which encodes the enzyme kynureninase. Other genes in the pathway include KMO, KYAT1-3, TDO2, IDO1, IDO2, QPRT, HAAO, and ACMSD.
What is the role of kynureninase in tryptophan metabolism?
Kynureninase converts L-kynurenine to anthranilate, directing the kynurenine pathway toward NAD+ synthesis and away from neuroactive metabolites like kynurenic acid and quinolinic acid.
What diseases are associated with kynureninase deficiency?
Kynureninase deficiency causes NAD deficiency and congenital malformations, which can be rescued by niacin supplementation in model systems.
Is kynureninase involved in cancer?
Yes, elevated kynureninase activity is associated with breast cancer metastasis progression, and kynureninase-expressing antigen-presenting cells can suppress CD8 T cell responses.
How is kynureninase activity measured?
It is measured using enzymatic assays that monitor the conversion of L-kynurenine to anthranilate, often with HPLC or spectrophotometry, as well as metabolomics.
What cofactor does kynureninase require?
Kynureninase is a pyridoxal-5'-phosphate (PLP)-dependent enzyme.
Can CRISPR be used to study kynureninase activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect the function of KYNU and kynureninase activity.
What is the GO ID for kynureninase activity?
The GO ID is GO:0030429.
What are the synonyms for kynureninase activity?
The synonyms are kynurenine hydrolase activity and L-kynurenine hydrolase activity.
Conclusion
Kynureninase activity (GO:0030429) is a critical enzymatic function in the kynurenine pathway, controlling the balance between NAD+ synthesis and neuroactive metabolite production. Its dysregulation is linked to congenital malformations, cancer progression, and immune tolerance. CRISPR-based models offer powerful tools to study the causal role of kynureninase in these processes, and EDITGENE provides comprehensive services to support such research.
References
- 1. Kesarwani P et al.. 2023. Quinolinate promotes macrophage-induced immune tolerance in glioblastoma through the NMDAR/PPARγ signaling axis.. Nat Commun 14(1):1459 PMID: 36927729
- 2. Phillips RS. 2014. Structure and mechanism of kynureninase.. Arch Biochem Biophys 544:69-74 PMID: 24200862
- 3. Badawy AA. 2017. Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects.. Int J Tryptophan Res 10:1178646917691938 PMID: 28469468
- 5. Shi H et al.. 2017. NAD Deficiency, Congenital Malformations, and Niacin Supplementation.. N Engl J Med 377(6):544-552 PMID: 28792876
- 6. Girithar HN et al.. 2024. Breast cancer metastasis progression is associated with elevated activity of kynurenine monooxygenase and kynureninase.. Br J Cancer 131(12):1881-1892 PMID: 39558063
- 7. Giacomantonio MA et al.. 2026. Subversion of kynurenine-induced AHR activation in CD8 T cells by kynureninase-expressing antigen-presenting cells.. Cell Rep 45(4):117149 PMID: 41863799
- 8. Yin J et al.. 2026. Regulating Tumor Metabolic Reprogramming with Biomimetic Co-Delivery of Simvastatin and Kynureninase for Immunotherapy.. Adv Sci (Weinh) 13(12):e08107 PMID: 41432057
